Lundbeck Highlights Vyepti Potential, But Company's 2021 Outlook Cautious
Long-Acting Migraine Therapy Awaiting Approval In 12 Markets
Executive Summary
Lundbeck is focused on the global launch of its new migraine therapy Vyepti in the coming years, and the development of additional indications, as its reported a 4% increase in revenues in 2020 which were within its pre-pandemic guidance.
You may also be interested in...
Pipeline Watch: Phase III Readouts For Dry Eye, Menopause
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
UCB And Microsoft Expand AI Tie-Up Beyond COVID-19
Two European pharmaceutical companies, UCB and Merck KGaA, are exploring artificial intelligence in different ways, the first for drug discovery and the second on a fundamental level.
Italfarmaco's Givinostat Encouraging In DMD, But Awaiting 2022 Pivotal Study Results
Italy’s Italfarmaco expects top-line data from its pivotal Phase III study of givinostat in Duchenne muscular dystrophy in the middle of next year, as the HDAC inhibitor continues to accrue data from the extension of its Phase II study.
Need a specific report? 1000+ reports available
Buy Reports